Autolus Therapeutics (NASDAQ:AUTL) Stock Rating Upgraded by Truist Financial

Key Points

• Truist Financial upgraded Autolus Therapeutics (NASDAQ:AUTL) to a "strong-buy" rating in a report released Wednesday.
• Analysts are mixed—one Strong Buy, four Buy, one Hold and one Sell—resulting in a MarketBeat consensus of "Moderate Buy" with an average price target of $8.50, far above the current share price.
• Shares opened at $1.33 (52‑week range $1.11–$2.70) with a market cap of about $354 million and a negative PE, and institutional investors own roughly 72.8% of the stock.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) was upgraded by stock analysts at Truist Financial to a "strong-buy" rating in a report released on Wednesday,Zacks.com reports.

Other analysts have also issued reports about the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Autolus Therapeutics in a research note on Wednesday, January 21st. HC Wainwright initiated coverage on Autolus Therapeutics in a research note on Tuesday, February 17th. They set a "buy" rating and a $9.00 target price for the company. Zacks Research raised shares of Autolus Therapeutics from a "strong sell" rating to a "hold" rating in a report on Friday, March 13th. Finally, Needham & Company LLC reduced their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $8.50.

Autolus Therapeutics Price Performance

NASDAQ AUTL opened at $1.33 on Wednesday. The business has a fifty day moving average price of $1.49 and a two-hundred day moving average price of $1.52. The stock has a market capitalization of $353.97 million, a PE ratio of -1.60 and a beta of 1.95. Autolus Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $2.70.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Marex Group plc acquired a new position in Autolus Therapeutics in the 2nd quarter worth about $28,000. Independent Advisor Alliance acquired a new stake in shares of Autolus Therapeutics during the fourth quarter valued at about $28,000. SmartHarvest Portfolios LLC bought a new stake in shares of Autolus Therapeutics during the fourth quarter worth about $43,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Autolus Therapeutics during the third quarter worth about $46,000. Finally, R Squared Ltd increased its stake in shares of Autolus Therapeutics by 40.1% in the third quarter. R Squared Ltd now owns 30,476 shares of the company's stock valued at $50,000 after buying an additional 8,730 shares during the period. Institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.